BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: PR Newswire
TROY, Mich., March 6, 2026 /PRNewswire/ -- Equifax Inc.'s recent report has investors wondering if the company's stock is fairly valued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers Equifax (NYSE: EFX) as worthy of further study and has named the company its "Stock to Study" for the May 2026 issue for investors' informational and educational use.The fundamental data is eye-opening; investors can view Equifax's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors Corp., at: https://ssg.betterinvesting.org/trial/ssgplus/?ticker=EFX.A full report on Equifax will appear in the May 2026 issue of BetterInvesting Magazine. The same issue of BetterInvesting Magazine will also include a fundamental review of Neurocrine Bio In. (NASDAQ: NBIX), which the independent Editorial Advisory and Securities Review Committee believes is worthy of fu
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences, Inc. (NBIX) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]Seeking Alpha
- Neurocrine Biosciences (NBIX) was upgraded by Wolfe Research to "strong-buy".MarketBeat
- Neurocrine Biosciences to Present at Upcoming Investor Conferences in March [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences to Present at Upcoming Investor Conferences in MarchPR Newswire
- Neurocrine Biosciences (NASDAQ:NBIX) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $160.00 price target on the stock.MarketBeat
NBIX
Earnings
- 2/11/26 - Beat
NBIX
Sec Filings
- 3/5/26 - Form 4
- 2/23/26 - Form 4
- 2/17/26 - Form 4
- NBIX's page on the SEC website